MicroRNA in Gastrointestinal Cancer. A Step Closer to Reality.

Advances in Clinical Chemistry

Volumn 62, Issue , 2013, Pages 221-268

  Link, Alexander ^a   Goel, Ajay ^b  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Biomarker; Cancer; Colorectal cancer; DNA methylation; Epigenetics; Fecal; Gastric cancer; Gastrointestinal cancer; Hepatocellular carcinoma; MicroRNA; MiRNA; Noninvasive; Pancreatic cancer; Plasma; Serum

Indexed keywords

MICRORNA; TUMOR MARKER;

ARTICLE; BLOOD; CHEMISTRY; FECES; GASTROINTESTINAL TUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; PROGNOSIS; RNA STABILITY;

FECES; GASTROINTESTINAL NEOPLASMS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; PROGNOSIS; RNA STABILITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84888397131     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-800096-0.00006-8     Document Type: Chapter

References (130)

1. Jemal A., Center M.M., DeSantis C., Ward E.M. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol. Biomarkers Prev. 2010, 19(8):1893-1907.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 2012, 62(1):10-29.
3. Mukherji S., Ebert M.S., Zheng G.X., Tsang J.S., Sharp P.A., van Oudenaarden A. MicroRNAs can generate thresholds in target gene expression. Nat. Genet. 2011, 43(9):854-859.
4. Goel A., Boland C.R. Epigenetics of colorectal cancer. Gastroenterology 2012, 143(6):1442-1460.
5. Lee R.C., Feinbaum R.L., Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993, 75(5):843-854.
6. Wightman B., Ha I., Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 1993, 75(5):855-862.
7. Lagos-Quintana M., Rauhut R., Lendeckel W., Tuschl T. Identification of novel genes coding for small expressed RNAs. Science 2001, 294(5543):853-858.
8. Ambros V. The functions of animal microRNAs. Nature 2004, 431(7006):350-355.
9. Calin G.A., Croce C.M. MicroRNA signatures in human cancers. Nat. Rev. Cancer 2006, 6(11):857-866.
10. Filipowicz W., Bhattacharyya S.N., Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?. Nat. Rev. Genet. 2008, 9(2):102-114.
11. He L., Hannon G.J. MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet. 2004, 5(7):522-531.
12. Kozomara A., Griffiths-Jones S. miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res. 2011, 39(Database issue):D152-D157.
13. Griffiths-Jones S. The microRNA registry. Nucleic Acids Res. 2004, 32(Database issue):D109-D111.
14. Lewis B.P., Burge C.B., Bartel D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120(1):15-20.
15. Balaguer F., Link A., Lozano J.J., Cuatrecasas M., Nagasaka T., Boland C.R., Goel A. Epigenetic silencing of miR-137 is an early event in colorectal carcinogenesis. Cancer Res. 2010, 70(16):6609-6618.
16. Saito Y., Jones P.A. Epigenetic activation of tumor suppressor microRNAs in human cancer cells. Cell Cycle 2006, 5(19):2220-2222.
17. Sampath D., Liu C., Vasan K., Sulda M., Puduvalli V.K., Wierda W.G., Keating M.J. Histone deacetylases mediate the silencing of miR-15a, miR-16 and miR-29b in chronic lymphocytic leukemia. Blood 2011, 119(5):1162-1172.
18. Bushati N., Cohen S.M. microRNA functions. Annu. Rev. Cell Dev. Biol. 2007, 23:175-205.
19. Lee Y., Ahn C., Han J., Choi H., Kim J., Yim J., Lee J., Provost P., Radmark O., Kim S., Kim V.N. The nuclear RNase III Drosha initiates microRNA processing. Nature 2003, 425(6956):415-419.
20. Filipowicz W., Jaskiewicz L., Kolb F.A., Pillai R.S. Post-transcriptional gene silencing by siRNAs and miRNA. Curr. Opin. Struct. Biol. 2005, 15(3):331-341.
21. Liu J., Carmell M.A., Rivas F.V., Marsden C.G., Thomson J.M., Song J.J., Hammond S.M., Joshua-Tor L., Hannon G.J. Argonaute2 is the catalytic engine of mammalian RNAi. Science 2004, 305(5689):1437-1441.
22. Croce C.M. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 2009, 10(10):704-714.
23. Vasudevan S., Tong Y., Steitz J.A. Switching from repression to activation: microRNAs can up-regulate translation. Science 2007, 318(5858):1931-1934.
24. Zisoulis D.G., Kai Z.S., Chang R.K., Pasquinelli A.E. Autoregulation of microRNA biogenesis by let-7 and Argonaute. Nature 2012, 486(7404):541-544.
25. Tang R., Li L., Zhu D., Hou D., Cao T., Gu H., Zhang J., Chen J., Zhang C.Y., Zen K. Mouse miRNA-709 directly regulates miRNA-15a/16-1 biogenesis at the posttranscriptional level in the nucleus: evidence for a microRNA hierarchy system. Cell Res. 2012, 22(3):504-515.
26. Link A., Kupcinskas J., Wex T., Malfertheiner P. Macro-role of microRNA in gastric cancer. Dig. Dis. 2012, 30(3):255-267.
27. Song J.H., Meltzer S.J. MicroRNAs in pathogenesis, diagnosis, and treatment of gastroesophageal cancers. Gastroenterology 2012, 143(1):35-47.
28. Lu J., Getz G., Miska E.A., Alvarez-Saavedra E., Lamb J., Peck D., Sweet-Cordero A., Ebert B.L., Mak R.H., Ferrando A.A., Downing J.R., Jacks T., Horvitz H.R., Golub T.R. MicroRNA expression profiles classify human cancers. Nature 2005, 435(7043):834-838.
29. Volinia S., Calin G.A., Liu C.G., Ambs S., Cimmino A., Petrocca F., Visone R., Iorio M., Roldo C., Ferracin M., Prueitt R.L., Yanaihara N., Lanza G., Scarpa A., Vecchione A., Negrini M., Harris C.C., Croce C.M. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. U.S.A. 2006, 103(7):2257-2261.
30. Calin G.A., Ferracin M., Cimmino A., Di Leva G., Shimizu M., Wojcik S.E., Iorio M.V., Visone R., Sever N.I., Fabbri M., Iuliano R., Palumbo T., Pichiorri F., Roldo C., Garzon R., Sevignani C., Rassenti L., Alder H., Volinia S., Liu C.G., Kipps T.J., Negrini M., Croce C.M. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N. Engl. J. Med. 2005, 353(17):1793-1801.
31. Balaguer F., Moreira L., Lozano J.J., Link A., Ramirez G., Shen Y., Cuatrecasas M., Arnold M., Meltzer S.J., Syngal S., Stoffel E., Jover R., Llor X., Castells A., Boland C.R., Gironella M., Goel A. Colorectal cancers with microsatellite instability display unique miRNA profiles. Clin. Cancer Res. 2011, 17(19):6239-6249.
32. Lawrie C.H., Gal S., Dunlop H.M., Pushkaran B., Liggins A.P., Pulford K., Banham A.H., Pezzella F., Boultwood J., Wainscoat J.S., Hatton C.S., Harris A.L. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br. J. Haematol. 2008, 141(5):672-675.
33. Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L., Peterson A., Noteboom J., O'Briant K.C., Allen A., Lin D.W., Urban N., Drescher C.W., Knudsen B.S., Stirewalt D.L., Gentleman R., Vessella R.L., Nelson P.S., Martin D.B., Tewari M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U.S.A. 2008, 105(30):10513-10518.
34. Chen X., Ba Y., Ma L., Cai X., Yin Y., Wang K., Guo J., Zhang Y., Chen J., Guo X., Li Q., Li X., Wang W., Zhang Y., Wang J., Jiang X., Xiang Y., Xu C., Zheng P., Zhang J., Li R., Zhang H., Shang X., Gong T., Ning G., Wang J., Zen K., Zhang J., Zhang C.Y. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008, 18(10):997-1006.
35. Weber J.A., Baxter D.H., Zhang S., Huang D.Y., Huang K.H., Lee M.J., Galas D.J., Wang K. The microRNA spectrum in 12 body fluids. Clin. Chem. 2010, 56(11):1733-1741.
36. Xing L., Todd N.W., Yu L., Fang H., Jiang F. Early detection of squamous cell lung cancer in sputum by a panel of microRNA markers. Mod. Pathol. 2010, 23(8):1157-1164.
37. Link A., Balaguer F., Shen Y., Nagasaka T., Lozano J.J., Boland C.R., Goel A. Fecal microRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol. Biomarkers Prev. 2010, 19(7):1766-1774.
38. Pigati L., Yaddanapudi S.C., Iyengar R., Kim D.J., Hearn S.A., Danforth D., Hastings M.L., Duelli D.M. Selective release of microRNA species from normal and malignant mammary epithelial cells. PLoS One 2010, 5(10):e13515.
39. Murata K., Yoshitomi H., Tanida S., Ishikawa M., Nishitani K., Ito H., Nakamura T. Plasma and synovial fluid microRNAs as potential biomarkers of rheumatoid arthritis and osteoarthritis. Arthritis Res. Ther. 2010, 12(3):R86.
40. Baraniskin A., Kuhnhenn J., Schlegel U., Chan A., Deckert M., Gold R., Maghnouj A., Zollner H., Reinacher-Schick A., Schmiegel W., Hahn S.A., Schroers R. Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood 2011, 117(11):3140-3146.
41. Pritchard C.C., Kroh E., Wood B., Arroyo J.D., Dougherty K.J., Miyaji M.M., Tait J.F., Tewari M. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev. Res. (Phila) 2012, 5(3):492-497.
42. Duttagupta R., Jiang R., Gollub J., Getts R.C., Jones K.W. Impact of cellular miRNA on circulating miRNA biomarker signatures. PLoS One 2011, 6(6):e20769.
43. Valadi H., Ekstrom K., Bossios A., Sjostrand M., Lee J.J., Lotvall J.O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 2007, 9(6):654-659.
44. Hunter M.P., Ismail N., Zhang X., Aguda B.D., Lee E.J., Yu L., Xiao T., Schafer J., Lee M.L., Schmittgen T.D., Nana-Sinkam S.P., Jarjoura D., Marsh C.B. Detection of microRNA expression in human peripheral blood microvesicles. PLoS One 2008, 3(11):e3694.
45. Arroyo J.D., Chevillet J.R., Kroh E.M., Ruf I.K., Pritchard C.C., Gibson D.F., Mitchell P.S., Bennett C.F., Pogosova-Agadjanyan E.L., Stirewalt D.L., Tait J.F., Tewari M. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc. Natl. Acad. Sci. U.S.A. 2011, 108(12):5003-5008.
46. Turchinovich A., Weiz L., Langheinz A., Burwinkel B. Characterization of extracellular circulating microRNA. Nucleic Acids Res. 2011, 39(16):7223-7233.
47. Winter J., Diederichs S. Argonaute proteins regulate microRNA stability: Increased microRNA abundance by Argonaute proteins is due to microRNA stabilization. RNA Biol. 2011, 8(6):1149-1157.
48. Vickers K.C., Palmisano B.T., Shoucri B.M., Shamburek R.D., Remaley A.T. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat. Cell Biol. 2011, 13(4):423-433.
49. McKenna L.B., Schug J., Vourekas A., McKenna J.B., Bramswig N.C., Friedman J.R., Kaestner K.H. MicroRNAs control intestinal epithelial differentiation, architecture, and barrier function. Gastroenterology 2010, 139(5):1654-1664.
50. Kalimutho M., Del Vecchio B.G., Di Cecilia S., Sileri P., Cretella M., Pallone F., Federici G., Bernardini S. Differential expression of miR-144* as a novel fecal-based diagnostic marker for colorectal cancer. J. Gastroenterol. 2011, 46(12):1391-1402.
51. Link A., Becker V., Goel A., Wex T., Malfertheiner P. Feasibility of fecal microRNAs as novel biomarkers for pancreatic cancer. PLoS One 2012, 7(8):e42933.
52. Wu C.W., Ng S.S., Dong Y.J., Ng S.C., Leung W.W., Lee C.W., Wong Y.N., Chan F.K., Yu J., Sung J.J. Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps. Gut 2012, 61(5):739-745.
53. Cortez M.A., Bueso-Ramos C., Ferdin J., Lopez-Berestein G., Sood A.K., Calin G.A. MicroRNAs in body fluids-the mix of hormones and biomarkers. Nat. Rev. Clin. Oncol. 2011, 8(8):467-477.
54. Patnaik S.K., Mallick R., Yendamuri S. Detection of microRNAs in dried serum blots. Anal. Biochem. 2010, 407(1):147-149.
55. Schuster C., Budczies J., Faber C., Kirchner T., Hlubek F. MicroRNA expression profiling of specific cells in complex archival tissue stained by immunohistochemistry. Lab. Invest. 2011, 91(1):157-165.
56. Gee H.E., Buffa F.M., Camps C., Ramachandran A., Leek R., Taylor M., Patil M., Sheldon H., Betts G., Homer J., West C., Ragoussis J., Harris A.L. The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis. Br. J. Cancer 2011, 104(7):1168-1177.
57. Zhang C., Wang C., Chen X., Yang C., Li K., Wang J., Dai J., Hu Z., Zhou X., Chen L., Zhang Y., Li Y., Qiu H., Xing J., Liang Z., Ren B., Yang C., Zen K., Zhang C.Y. Expression profile of microRNAs in serum: a fingerprint for esophageal squamous cell carcinoma. Clin. Chem. 2010, 56(12):1871-1879.
58. Kurashige J., Kamohara H., Watanabe M., Tanaka Y., Kinoshita K., Saito S., Hiyoshi Y., Iwatsuki M., Baba Y., Baba H. Serum microRNA-21 is a novel biomarker in patients with esophageal squamous cell carcinoma. J. Surg. Oncol. 2012, 106(2):188-192.
59. Cai E.H., Gao Y.X., Wei Z.Z., Chen W.Y., Yu P., Li K. Serum miR-21 expression in human esophageal squamous cell carcinomas. Asian Pac. J. Cancer Prev. 2012, 13(4):1563-1567.
60. Zhang T., Zhao D., Wang Q., Yu X., Cui Y., Guo L., Lu S.H. MicroRNA-1322 regulates ECRG2 allele specifically and acts as a potential biomarker in patients with esophageal squamous cell carcinoma. Mol. Carcinog. 2013, 52(8):581-590.
61. Komatsu S., Ichikawa D., Takeshita H., Tsujiura M., Morimura R., Nagata H., Kosuga T., Iitaka D., Konishi H., Shiozaki A., Fujiwara H., Okamoto K., Otsuji E. Circulating microRNAs in plasma of patients with oesophageal squamous cell carcinoma. Br. J. Cancer 2011, 105(1):104-111.
62. Zhang T., Wang Q., Zhao D., Cui Y., Cao B., Guo L., Lu S.H. The oncogenetic role of microRNA-31 as a potential biomarker in oesophageal squamous cell carcinoma. Clin. Sci. (Lond.) 2011, 121(10):437-447.
63. Bansal A., Lee I.H., Hong X., Anand V., Mathur S.C., Gaddam S., Rastogi A., Wani S.B., Gupta N., Visvanathan M., Sharma P., Christenson L.K. Feasibility of mcroRNAs as biomarkers for Barrett's Esophagus progression: a pilot cross-sectional, phase 2 biomarker study. Am. J. Gastroenterol. 2011, 106(6):1055-1063.
64. Fassan M., Volinia S., Palatini J., Pizzi M., Baffa R., De Bernard M., Battaglia G., Parente P., Croce C.M., Zaninotto G., Ancona E., Rugge M. MicroRNA expression profiling in human Barrett's carcinogenesis. Int. J. Cancer 2011, 129(7):1661-1670.
65. Fukayama M., Chong J.M., Uozaki H. Pathology and molecular pathology of Epstein-Barr virus-associated gastric carcinoma. Curr. Top. Microbiol. Immunol. 2001, 258:91-102.
66. Li B.S., Zhao Y.L., Guo G., Li W., Zhu E.D., Luo X., Mao X.H., Zou Q.M., Yu P.W., Zuo Q.F., Li N., Tang B., Liu K.Y., Xiao B. Plasma microRNAs, miR-223, miR-21 and miR-218, as novel potential biomarkers for gastric cancer detection. PLoS One 2012, 7(7):e41629.
67. Zhou H., Xiao B., Zhou F., Deng H., Zhang X., Lou Y., Gong Z., Du C., Guo J. MiR-421 is a functional marker of circulating tumor cells in gastric cancer patients. Biomarkers 2012, 17(2):104-110.
68. Song M.Y., Pan K.F., Su H.J., Zhang L., Ma J.L., Li J.Y., Yuasa Y., Kang D., Kim Y.S., You W.C. Identification of serum microRNAs as novel non-invasive biomarkers for early detection of gastric cancer. PLoS One 2012, 7(3):e33608.
69. Wang M., Gu H., Wang S., Qian H., Zhu W., Zhang L., Zhao C., Tao Y., Xu W. Circulating miR-17-5p and miR-20a: molecular markers for gastric cancer. Mol. Med. Rep. 2012, 5(6):1514-1520.
70. Konishi H., Ichikawa D., Komatsu S., Shiozaki A., Tsujiura M., Takeshita H., Morimura R., Nagata H., Arita T., Kawaguchi T., Hirashima S., Fujiwara H., Okamoto K., Otsuji E. Detection of gastric cancer-associated microRNAs on microRNA microarray comparing pre- and post-operative plasma. Br. J. Cancer 2012, 106(4):740-747.
71. Liu H., Zhu L., Liu B., Yang L., Meng X., Zhang W., Ma Y., Xiao H. Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer. Cancer Lett. 2012, 316(2):196-203.
72. Lo S.S., Hung P.S., Chen J.H., Tu H.F., Fang W.L., Chen C.Y., Chen W.T., Gong N.R., Wu C.W. Overexpression of miR-370 and downregulation of its novel target TGFbeta-RII contribute to the progression of gastric carcinoma. Oncogene 2012, 31(2):226-237.
73. Zheng Y., Cui L., Sun W., Zhou H., Yuan X., Huo M., Chen J., Lou Y., Guo J. MicroRNA-21 is a new marker of circulating tumor cells in gastric cancer patients. Cancer Biomark. 2011, 10(2):71-77.
74. Liu R., Zhang C., Hu Z., Li G., Wang C., Yang C., Huang D., Chen X., Zhang H., Zhuang R., Deng T., Liu H., Yin J., Wang S., Zen K., Ba Y., Zhang C.Y. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur. J. Cancer 2011, 47(5):784-791.
75. Zhou H., Guo J.M., Lou Y.R., Zhang X.J., Zhong F.D., Jiang Z., Cheng J., Xiao B.X. Detection of circulating tumor cells in peripheral blood from patients with gastric cancer using microRNA as a marker. J. Mol. Med. (Berl) 2010, 88(7):709-717.
76. Tsujiura M., Ichikawa D., Komatsu S., Shiozaki A., Takeshita H., Kosuga T., Konishi H., Morimura R., Deguchi K., Fujiwara H., Okamoto K., Otsuji E. Circulating microRNAs in plasma of patients with gastric cancers. Br. J. Cancer 2010, 102(7):1174-1179.
77. Bandres E., Bitarte N., Arias F., Agorreta J., Fortes P., Agirre X., Zarate R., Diaz-Gonzalez J.A., Ramirez N., Sola J.J., Jimenez P., Rodriguez J., Garcia-Foncillas J. microRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells. Clin. Cancer Res. 2009, 15(7):2281-2290.
78. Brenner B., Hoshen M.B., Purim O., David M.B., Ashkenazi K., Marshak G., Kundel Y., Brenner R., Morgenstern S., Halpern M., Rosenfeld N., Chajut A., Niv Y., Kushnir M. MicroRNAs as a potential prognostic factor in gastric cancer. World J. Gastroenterol. 2011, 17(35):3976-3985.
79. Li X., Zhang Y., Zhang Y., Ding J., Wu K., Fan D. Survival prediction of gastric cancer by a seven-microRNA signature. Gut 2010, 59(5):579-585.
80. Tchernitsa O., Kasajima A., Schafer R., Kuban R.J., Ungethum U., Gyorffy B., Neumann U., Simon E., Weichert W., Ebert M.P., Rocken C. Systematic evaluation of the miRNA-ome and its downstream effects on mRNA expression identifies gastric cancer progression. J. Pathol. 2010, 222(3):310-319.
81. Ueda T., Volinia S., Okumura H., Shimizu M., Taccioli C., Rossi S., Alder H., Liu C.G., Oue N., Yasui W., Yoshida K., Sasaki H., Nomura S., Seto Y., Kaminishi M., Calin G.A., Croce C.M. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol. 2010, 11(2):136-146.
82. Giraldez M.D., Lozano J.J., Ramirez G., Hijona E., Bujanda L., Castells A., Gironella M. Circulating microRNAs as biomarkers of colorectal cancer: results from a genome-wide profiling and validation study. Clin. Gastroenterol. Hepatol. 2013, 11:681-688.
83. Kanaan Z., Rai S.N., Eichenberger M.R., Roberts H., Keskey B., Pan J., Galandiuk S. Plasma miR-21: a potential diagnostic marker of colorectal cancer. Ann. Surg. 2012, 256(3):544-551.
84. Ahmed F.E., Amed N.C., Vos P.W., Bonnerup C., Atkins J.N., Casey M., Nuovo G.J., Naziri W., Wiley J.E., Allison R.R. Diagnostic microRNA markers to screen for sporadic human colon cancer in blood. Cancer Genomics Proteomics 2012, 9(4):179-192.
85. Nugent M., Miller N., Kerin M.J. Circulating miR-34a levels are reduced in colorectal cancer. J. Surg. Oncol. 2012, 106(8):947-952.
86. Wang L.G., Gu J. Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis. Cancer Epidemiol. 2012, 36(1):e61-e67.
87. Cheng H., Zhang L., Cogdell D.E., Zheng H., Schetter A.J., Nykter M., Arris C.C.H., Chen K., Hamilton S.R., Zhang W. Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One 2011, 6(3):e17745.
88. Pu X.X., Huang G.L., Guo H.Q., Guo C.C., Li H., Ye S., Ling S., Jiang L., Tian Y., Lin T.Y. Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J. Gastroenterol. Hepatol. 2010, 25(10):1674-1680.
89. Huang Z., Huang D., Ni S., Peng Z., Sheng W., Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int. J. Cancer 2010, 127(1):118-126.
90. Ng E.K., Chong W.W., Jin H., Lam E.K., Shin V.Y., Yu J., Poon T.C., Ng S.S., Sung J.J. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009, 58(10):1375-1381.
91. Li J.M., Zhao R.H., Li S.T., Xie C.X., Jiang H.H., Ding W.J., Du P., Chen W., Yang M., Cui L. Down-regulation of fecal miR-143 and miR-145 as potential markers for colorectal cancer. Saudi Med. J. 2012, 33(1):24-29.
92. Kalimutho M., Di Cecilia S., Del Vecchio B.G., Roviello F., Sileri P., Cretella M., Formosa A., Corso G., Marrelli D., Pallone F., Federici G., Bernardini S. Epigenetically silenced miR-34b/c as a novel faecal-based screening marker for colorectal cancer. Br. J. Cancer 2011, 104(11):1770-1778.
93. Koga Y., Yasunaga M., Takahashi A., Kuroda J., Moriya Y., Akasu T., Fujita S., Yamamoto S., Baba H., Matsumura Y. MicroRNA expression profiling of exfoliated colonocytes isolated from feces for colorectal cancer screening. Cancer Prev. Res. (Phila) 2010, 3(11):1435-1442.
94. Ahmed F.E., Jeffries C.D., Vos P.W., Flake G., Nuovo G.J., Sinar D.R., Naziri W., Marcuard S.P. Diagnostic microRNA markers for screening sporadic human colon cancer and active ulcerative colitis in stool and tissue. Cancer Genomics Proteomics 2009, 6(5):281-295.
95. Ren Y., Gao J., Liu J.Q., Wang X.W., Gu J.J., Huang H.J., Gong Y.F., Li Z.S. Differential signature of fecal microRNAs in patients with pancreatic cancer. Mol. Med. Rep. 2012, 6(1):201-209.
96. Ghaneh P., Costello E., Neoptolemos J.P. Biology and management of pancreatic cancer. Postgrad. Med. J. 2008, 84(995):478-497.
97. La V.C., Bosetti C., Lucchini F., Bertuccio P., Negri E., Boyle P., Levi F. Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975. Ann. Oncol. 2010, 21(6):1323-1360.
98. Siegel R., DeSantis C., Virgo K., Stein K., Mariotto A., Smith T., Cooper D., Gansler T., Lerro C., Fedewa S., Lin C., Leach C., Cannady R.S., Cho H., Scoppa S., Hachey M., Kirch R., Jemal A., Ward E. Cancer treatment and survivorship statistics, 2012. CA Cancer J. Clin. 2012, 62(4):220-241.
99. Bauer A.S., Keller A., Costello E., Greenhalf W., Bier M., Borries A., Beier M., Neoptolemos J., Buchler M., Werner J., Giese N., Hoheisel J.D. Diagnosis of pancreatic ductal adenocarcinoma and chronic pancreatitis by measurement of microRNA abundance in blood and tissue. PLoS One 2012, 7(4):e34151.
100. Liu R., Chen X., Du Y., Yao W., Shen L., Wang C., Hu Z., Zhuang R., Ning G., Zhang C., Yuan Y., Li Z., Zen K., Ba Y., Zhang C.Y. Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clin. Chem. 2012, 58(3):610-618.
101. Morimura R., Komatsu S., Ichikawa D., Takeshita H., Tsujiura M., Nagata H., Konishi H., Shiozaki A., Ikoma H., Okamoto K., Ochiai T., Taniguchi H., Otsuji E. Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer. Br. J. Cancer 2011, 105(11):1733-1740.
102. Liu J., Gao J., Du Y., Li Z., Ren Y., Gu J., Wang X., Gong Y., Wang W., Kong X. Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer. Int. J. Cancer 2012, 131(3):683-691.
103. LaConti J.J., Shivapurkar N., Preet A., Deslattes M.A., Peran I., Kim S.E., Marshall J.L., Riegel A.T., Wellstein A. Tissue and serum microRNAs in the Kras(G12D) transgenic animal model and in patients with pancreatic cancer. PLoS One 2011, 6(6):e20687.
104. Ali S., Almhanna K., Chen W., Philip P.A., Sarkar F.H. Differentially expressed miRNA in the plasma may provide a molecular signature for aggressive pancreatic cancer. Am. J. Transl. Res. 2010, 3(1):28-47.
105. Kong X., Du Y., Wang G., Gao J., Gong Y., Li L., Zhang Z., Zhu J., Jing Q., Qin Y., Li Z. Detection of differentially expressed microRNAs in serum of pancreatic ductal adenocarcinoma patients: miR-196a could be a potential marker for poor prognosis. Dig. Dis. Sci. 2011, 56(2):602-609.
106. Li A., Omura N., Hong S.M., Vincent A., Walter K., Griffith M., Borges M., Goggins M. Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Res. 2010, 70(13):5226-5237.
107. Ho A.S., Huang X., Cao H., Christman-Skieller C., Bennewith K., Le Q.T., Koong A.C. Circulating miR-210 as a novel hypoxia marker in pancreatic cancer. Transl. Oncol. 2010, 3(2):109-113.
108. Wang J., Chen J., Chang P., LeBlanc A., Li D., Abbruzzesse J.L., Frazier M.L., Killary A.M., Sen S. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev. Res. (Phila) 2009, 2(9):807-813.
109. Roldo C., Missiaglia E., Hagan J.P., Falconi M., Capelli P., Bersani S., Calin G.A., Volinia S., Liu C.G., Scarpa A., Croce C.M. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J. Clin. Oncol. 2006, 24(29):4677-4684.
110. Lee E.J., Gusev Y., Jiang J., Nuovo G.J., Lerner M.R., Frankel W.L., Morgan D.L., Postier R.G., Brackett D.J., Schmittgen T.D. Expression profiling identifies microRNA signature in pancreatic cancer. Int. J. Cancer 2007, 120(5):1046-1054.
111. Haug U., Wente M.N., Seiler C.M., Jesenofsky R., Brenner H. Stool testing for the early detection of pancreatic cancer: rationale and current evidence. Expert Rev. Mol. Diagn. 2008, 8(6):753-759.
112. Li L., Guo Z., Wang J., Mao Y., Gao Q. Serum miR-18a: a potential marker for hepatitis B virus-related hepatocellular carcinoma screening. Dig. Dis. Sci. 2012, 57:2910-2916.
113. Liu A.M., Yao T.J., Wang W., Wong K.F., Lee N.P., Fan S.T., Poon R.T., Gao C., Luk J.M. Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open 2012, 2(2):e000825.
114. Tomimaru Y., Eguchi H., Nagano H., Wada H., Kobayashi S., Marubashi S., Tanemura M., Tomokuni A., Takemasa I., Umeshita K., Kanto T., Doki Y., Mori M. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J. Hepatol. 2012, 56(1):167-175.
115. Qi P., Cheng S.Q., Wang H., Li N., Chen Y.F., Gao C.F. Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PLoS One 2011, 6(12):e28486.
116. Zhou J., Yu L., Gao X., Hu J., Wang J., Dai Z., Wang J.F., Zhang Z., Lu S., Huang X., Wang Z., Qiu S., Wang X., Yang G., Sun H., Tang Z., Wu Y., Zhu H., Fan J. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J. Clin. Oncol. 2011, 29(36):4781-4788.
117. Bihrer V., Waidmann O., Friedrich-Rust M., Forestier N., Susser S., Haupenthal J., Welker M., Shi Y., Peveling-Oberhag J., Polta A., von Wagner M., Radeke H.H., Sarrazin C., Trojan J., Zeuzem S., Kronenberger B., Piiper A. Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma. PLoS One 2011, 6(10):e26971.
118. Li J., Wang Y., Yu W., Chen J., Luo J. Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance. Biochem. Biophys. Res. Commun. 2011, 406(1):70-73.
119. Qu K.Z., Zhang K., Li H., Afdhal N.H., Albitar M. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J. Clin. Gastroenterol. 2011, 45(4):355-360.
120. Xu J., Wu C., Che X., Wang L., Yu D., Zhang T., Huang L., Li H., Tan W., Wang C., Lin D. Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol. Carcinog. 2011, 50(2):136-142.
121. Gui J., Tian Y., Wen X., Zhang W., Zhang P., Gao J., Run W., Tian L., Jia X., Gao Y. Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies. Clin. Sci. (Lond.) 2011, 120(5):183-193.
122. Li L.M., Hu Z.B., Zhou Z.X., Chen X., Liu F.Y., Zhang J.F., Shen H.B., Zhang C.Y., Zen K. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res. 2010, 70(23):9798-9807.
123. Shigoka M., Tsuchida A., Matsudo T., Nagakawa Y., Saito H., Suzuki Y., Aoki T., Murakami Y., Toyoda H., Kumada T., Bartenschlager R., Kato N., Ikeda M., Takashina T., Tanaka M., Suzuki R., Oikawa K., Takanashi M., Kuroda M. Deregulation of miR-92a expression is implicated in hepatocellular carcinoma development. Pathol. Int. 2010, 60(5):351-357.
124. Yamamoto Y., Kosaka N., Tanaka M., Koizumi F., Kanai Y., Mizutani T., Murakami Y., Kuroda M., Miyajima A., Kato T., Ochiya T. MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma. Biomarkers 2009, 14(7):529-538.
125. Shigehara K., Yokomuro S., Ishibashi O., Mizuguchi Y., Arima Y., Kawahigashi Y., Kanda T., Akagi I., Tajiri T., Yoshida H., Takizawa T., Uchida E. Real-time PCR-based analysis of the human bile microRNAome identifies miR-9 as a potential diagnostic biomarker for biliary tract cancer. PLoS One 2011, 6(8):e23584.
126. Zahm A.M., Hand N.J., Boateng L.A., Friedman J.R. Circulating microRNA is a biomarker of biliary atresia. J. Pediatr. Gastroenterol. Nutr. 2012, 55:366-369.
127. Neal C.S., Michael M.Z., Pimlott L.K., Yong T.Y., Li J.Y., Gleadle J.M. Circulating microRNA expression is reduced in chronic kidney disease. Nephrol. Dial. Transplant. 2011, 26(11):3794-3802.
128. Keller A., Leidinger P., Bauer A., Elsharawy A., Haas J., Backes C., Wendschlag A., Giese N., Tjaden C., Ott K., Werner J., Hackert T., Ruprecht K., Huwer H., Huebers J., Jacobs G., Rosenstiel P., Dommisch H., Schaefer A., Muller-Quernheim J., Wullich B., Keck B., Graf N., Reichrath J., Vogel B., Nebel A., Jager S.U., Staehler P., Amarantos I., Boisguerin V., Staehler C., Beier M., Scheffler M., Buchler M.W., Wischhusen J., Haeusler S.F., Dietl J., Hofmann S., Lenhof H.P., Schreiber S., Katus H.A., Rottbauer W., Meder B., Hoheisel J.D., Franke A., Meese E. Toward the blood-borne miRNome of human diseases. Nat. Methods 2011, 8(10):841-843.
129. McDonald J.S., Milosevic D., Reddi H.V., Grebe S.K., Algeciras-Schimnich A. Analysis of circulating microRNA: preanalytical and analytical challenges. Clin. Chem. 2011, 57(6):833-840.
130. Kim D.J., Linnstaedt S., Palma J., Park J.C., Ntrivalas E., Kwak-Kim J.Y., Gilman-Sachs A., Beaman K., Hastings M.L., Martin J.N., Duelli D.M. Plasma components affect accuracy of circulating cancer-related microRNA quantitation. J. Mol. Diagn. 2012, 14(1):71-80.